Provectus announces data from Phase 2 PV-10 metastatic melanoma study

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

More... (http://www.news-medical.net/news/20111111/Provectus-announces-data-from-Phase-2-PV-10-metastatic-melanoma-study.aspx)